Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

TNS Energy Yaroslavl reported for 2023 by IFRS

5/2/24 YRSB

Abrau-Durso reported for 2023 by IFRS

5/2/24 ABRD

Rosinter reported for 3 months of 2024 by RAS

5/2/24 ROST

M.video will sell refurbished devices

5/2/24 MVID

DZRD reported for 2023 by IFRS

5/2/24 DZRD

TNS Energo Voronezh reported for 3 months of 2024 by RAS

5/2/24 VRSB

Moscow Exchange disputes the seizure of SMZ shares

5/2/24 MGNZ

UTair reports for 2023 by IFRS

5/2/24 UTAR

Sollers reported for 2023 by IFR

5/2/24 SVAV

Buryatzoloto reported for 2023 by RAS

5/2/24 BRZL